Burning Rock Biotech (BNR) to Release Quarterly Earnings on Tuesday

Burning Rock Biotech (NASDAQ:BNR) is anticipated to issue its Q1 2026 results before the market opens on Tuesday, June 2nd. Analysts expect the company to announce earnings of ($2.2884) per share and revenue of $19.2070 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, June 4, 2026 at 12:30 PM ET.

Burning Rock Biotech (NASDAQ:BNR) last announced its quarterly earnings results on Saturday, February 14th. The company reported ($0.21) earnings per share (EPS) for the quarter. Burning Rock Biotech had a negative net margin of 10.27% and a negative return on equity of 9.98%. The company had revenue of $18.05 million during the quarter.

Burning Rock Biotech Price Performance

Shares of NASDAQ BNR opened at $14.51 on Tuesday. The stock has a market capitalization of $152.65 million, a price-to-earnings ratio of -18.37 and a beta of 1.49. Burning Rock Biotech has a 52 week low of $2.80 and a 52 week high of $41.72. The firm has a 50-day moving average price of $17.74 and a 200 day moving average price of $21.52.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Burning Rock Biotech in a report on Monday, April 20th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Insiders Place Their Bets

In other news, Director Yusheng Han bought 314,870 shares of the stock in a transaction on Tuesday, March 31st. The shares were bought at an average price of $17.36 per share, with a total value of $5,466,143.20. Following the completion of the acquisition, the director owned 17,672,676 shares of the company’s stock, valued at approximately $306,797,655.36. This trade represents a 1.81% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 30.30% of the company’s stock.

Institutional Investors Weigh In On Burning Rock Biotech

An institutional investor recently bought a new position in Burning Rock Biotech stock. Marshall Wace LLP acquired a new stake in Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 10,903 shares of the company’s stock, valued at approximately $220,000. Marshall Wace LLP owned about 0.10% of Burning Rock Biotech at the end of the most recent quarter. Hedge funds and other institutional investors own 30.03% of the company’s stock.

About Burning Rock Biotech

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.